Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In
  • Become a Member
  • MB Vision
  • Members
    • Become a Member
      • Types & Rates
    • Benefits
      • Savings and Rewards
    • Member News
    • Member Events
    • Career Center
    • Directory
    • Pay Company Dues
    • FAQs
  • Events
    • Upcoming
    • Types of Events
    • Sponsorship Opportunities
    • The State of Possible Conference
    • Align Summit
    • Member Events
  • Innovation
    • About
    • Drive
      • Application
      • Alumni
      • Partners – MassBio
      • Partners – SCbio
      • Get Involved
      • FAQs
    • CEO & Founder Link
    • Align Summit
    • Partnering
    • Sponsorship Opportunities
  • Savings
    • MassBioEdge
  • Conference Center
    • About MassBioHub
    • Packages & Special Offers
    • Venue Specifications
    • Reserve Today
  • Policy & Advocacy
    • Policy & Advocacy Efforts
    • Diversity, Equity, and Inclusion
      • DEI Report
      • Resource Center
      • Open Letter 2.0
      • Bioversity
    • Economic Development
      • BioReady® Communities
    • Workforce Development
      • Bioversity
    • Vision 2030
    • This is the place.
    • Industry Reports
      • Federal Actions Impact Report
      • Industry Snapshot
      • Biopharma Funding Report
      • DEI Report
      • MA Life Sciences Workforce
  • About
    • About MassBio
    • News & Thought Leadership
    • MB Vision
    • The Studio at Kendall Square
    • Sponsorship Opportunities
    • Staff
    • Board
    • Contact Us
  • Sign In
  • Become a Member
  • MB Vision
Open search form

Member Directory

Click to Open Main Menu

Vericel Corporation

Life Sciences | Drug Development
Cambridge, MA 617-588-5555 Website

Overview

Founded in 1989, Vericel (formerly Aastrom Biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in the United States, Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM).

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • News & Thought Leadership
  • Pay Company Dues
  • Join Today
  • Contact
  • Privacy Policy
  • © 2025 All Rights Reserved